Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2000

View Archived Issues

Meditech and Immune Network sign license option

Vion licenses potential HBV/HIV therapy to Achillion

IND filing in sight for new oral contraceptive

p38 MAPK inhibitor assessed in rat adjuvant-induced arthritis

Scios reviews 1999 developments

OxiGene highlights promising CA4P developments from Q4 and full year 1999

Generex initiates oral insulin trials in England

ID Biomedical's GAS vaccine well tolerated in early clinical testing

PPL Therapeutics' transgenic AAT shows promising results in phase II

Pharmacia & Upjohn in discussions with FDA regarding Vestra NDA

Major European introduction for Merck's COX-2 inhibitor

Microbiotix and BioChem Pharma to develop novel antibiotic agents

Miacalcin nasal spray receives Canadian approval as treatment for osteoporosis

Metabasis Therapeutics extends diabetes collaboration with Sankyo

Sulfonamide-based inhibitors of TNF-alpha production synthesized at Shionogi

New immunosuppressive agents derived from LK6-A

AHP prepares new rapamycin derivatives

SCRAS presents new class of NOS inhibitors and antioxidants

ORL1 antagonist J-113397 also being explored for cognition enhancement

Next-generation HBOCs in preclinical development at Hemosol

FDA issues approvable letter for Visudyne

UroGen cleared to begin phase I human clinical trial of gene therapy for hemophilia A

Clearance to begin clinical trial of novel acne treatment sought by Praxis

Preclinical studies support potential new indication for tamsulosin

FDA approves Actimmune for treatment of osteopetrosis

Novel Warner-Lambert compounds act as inhibitors of Lp(a) production

Components of naturally occurring antimicrobial complex isolated at Schering-Plough

Focal cerebral ischemic injury in rats improved by broad-spectrum ion channel blocker

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...